Immunology in Italy typically costs from $3,700 to $11,300. The total expense depends on whether you seek private treatment, the complexity of the immune disorder, and the specific therapy required, such as stem cells or biologics. Patients can expect 30-50% savings compared to the US.
Typical Immunology Costs in Italy
Most specialized immunology centers are located in Milan, Rome, and Genoa. While prices are relatively consistent across major medical hubs, a consultation with a specialist can help you get accurate pricing and a tailored treatment plan for your specific condition.
| Italia | España | Turquía | |
| Tratamiento de sangre de cordón umbilical | de $10,000 | de $7,500 | de $5,000 |
| Terapia intravenosa con curcumina | de $450 | de $450 | de $350 |
| Plasmaféresis | de $2,200 | de $1,800 | de $1,200 |
| Terapia de mejora inmunológica | de $3,800 | - | de $2,200 |
| Intercambio de plasma | de $2,250 | - | de $3,900 |
Bookimed no añade cargos extra a los precios de los tratamientos de Inmunología. Las tarifas proceden de las listas de precios oficiales de las clínicas. Pagará directamente en la clínica por su tratamiento a su llegada al país.
Bookimed está comprometido con su seguridad. Solo trabajamos con las clínicas que mantienen altos estándares internacionales en el tratamiento de Inmunología y tienen las licencias necesarias para atender a pacientes internacionales en todo el mundo.
Bookimed ofrece asistencia experta gratuita. Un coordinador médico personal le apoya antes, durante y después del tratamiento, resolviendo cualquier problema. Nunca estará solo en su viaje médico de procedimientos de Inmunología.
El Prof. Aiuti dirige investigaciones pioneras en terapia génica para inmunodeficiencias raras en el Hospital San Raffaele, con más de 180 publicaciones en la materia.
Reconocido como "Experto mundial en la enfermedad relacionada con la IgG4" por Expertscape, el Dr. Della Torre dirige clínicas especializadas en el Hospital San Raffaele.
Advanced cancer immunotherapies like CAR T-cell therapy are available in Italy. The Italian Medicines Agency (AIFA) authorizes these treatments for specific blood cancers. Leading centers in Milan and Rome provide clinical access. Specialized facilities like San Raffaele also offer advanced gene therapies.
Bookimed Expert Insight: Milan has become the primary hub for Italian immunotherapy. Clinics like San Raffaele combine research with clinical care, serving 300,000 patients annually. Our data shows these IRCCS-accredited centers often manage the highest volume of complex immune cases. Patients should target these large research hospitals to find the widest range of active clinical trials.
Patient Consensus: Patients note that while treatment is highly effective for blood cancers, the approval process can take three months. It is important to prepare for travel to major northern hubs like Milan because specialized care is rarely available at smaller local hospitals.
San Raffaele Hospital and Humanitas Research Hospital in Milan are globally recognized for treating rare immune disorders. San Raffaele pioneered the world first stem cell gene therapy for ADA-SCID. These centers hold IRCCS accreditation. This status marks them as premier Italian research institutes for molecular medicine.
Bookimed Expert Insight: Data shows that Milan is the primary hub for rare immunology. Clinics like San Raffaele and San Donato serve 300,000 patients yearly. Their IRCCS status is a key quality signal. This accreditation means they receive direct government funding for advanced clinical trials. Patients should prioritize these research-heavy centers for complex or undiagnosed immune conditions.
Patient Consensus: Patients note that San Raffaele is a top choice for primary immunodeficiencies and advanced trials. Many emphasize its collaboration with international institutions as a major factor for choosing Milan for rare disease care.
Italy offers new EMA-approved biologics like Anifrolumab for lupus and Bimekizumab for psoriatic arthritis. Targeted oral JAK inhibitors including Upadacitinib and Filgotinib are also widely available. These therapies are accessible through specialized IRCCS centers like San Raffaele and Humanitas Research Hospital in Milan.
Bookimed Expert Insight: Data from Milanese centers shows a high concentration of expertise in rare autoimmune conditions. Dr. Emanuele Della Torre at San Raffaele is a recognized global expert in IgG4-related diseases. Patients often find faster access to clinical trials and the latest AIFA-approved molecules at these research-heavy IRCCS institutions compared to general hospitals.
Patient Consensus: Patients note that starting documentation of previous treatment failures immediately helps speed up the approval process. Those treated in Northern Italy often report significantly shorter wait times for the newest drug listings than in Southern regions.
Allergen immunotherapy (AIT) accessibility in Italy remains highly variable due to regional reimbursement policies. The National Health System (SSN) covers grass pollen treatments for specific groups. However, patients often face full costs for other allergens like house dust mites depending on their local residence.
Bookimed Expert Insight: Patients seeking AIT should prioritize clinics with IRCCS accreditation, such as San Raffaele or San Donato. This Italian Ministry of Health certification signals a research-driven environment. These institutions often handle 300,000+ patients annually. Their high volume and academic links, featuring experts like Dr. Emanuele Della Torre, ensure access to the latest immunological protocols.
Patient Consensus: Patients note that sublingual therapy is the most convenient option for home use. Many emphasize the need to self-advocate or seek second opinions to successfully navigate the public reimbursement process.